KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Other Non Operating Income (2016 - 2025)

Pacira BioSciences (PCRX) has 15 years of Other Non Operating Income data on record, last reported at -$5.6 million in Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 10535.85% year-over-year to -$5.6 million; the TTM value through Dec 2025 reached -$12.9 million, down 5029.48%, while the annual FY2025 figure was -$6.6 million, 1674.8% down from the prior year.
  • Other Non Operating Income reached -$5.6 million in Q4 2025 per PCRX's latest filing, down from -$900000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $4.4 million in Q1 2025 and bottomed at -$16.9 million in Q1 2023.
  • Average Other Non Operating Income over 5 years is -$3.3 million, with a median of -$422000.0 recorded in 2023.
  • The widest YoY moves for Other Non Operating Income: up 2867.92% in 2025, down 27435.9% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at -$66000.0 in 2021, then tumbled by 17003.03% to -$11.3 million in 2022, then surged by 96.26% to -$422000.0 in 2023, then soared by 87.44% to -$53000.0 in 2024, then tumbled by 10535.85% to -$5.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$5.6 million in Q4 2025, -$900000.0 in Q3 2025, and -$10.7 million in Q2 2025.